Plasmid

Part:BBa_K5531008

Designed by: XI ZHAO   Group: iGEM24_SubCat-Union   (2024-09-02)
Revision as of 03:59, 30 September 2024 by Zmy0227 (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


pET-24a-PKG50-P4VP4


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 5062
    Illegal NotI site found at 5120
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 4957
    Illegal BglII site found at 6432
    Illegal BamHI site found at 5095
    Illegal XhoI site found at 5129
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 137
    Illegal NgoMIV site found at 3177
    Illegal NgoMIV site found at 3337
    Illegal NgoMIV site found at 4925
  • 1000
    COMPATIBLE WITH RFC[1000]


BBa_K5531008 (pET-24a-PKG50-P4VP4)

BBa_K5531008 (pET-24a-PKG50-P4VP4)

Construction Design

This targeted gene, PKG50-P4VP4 (BBa_K5531003), synthesized by a biotech company, contains proline-free heterotrimeric collagen-like protein motifs PKG fused with the P15VP4 protein. The pET24a (BBa_K5531005) serves as the vector. The homologous recombination method was employed for the construction of pET24a-PKG50-P4VP4 (BBa_K5531008).

Figure 1: Plasmid map of pET-24a-PKG50-P4VP4
Fig. 1. Plasmid map of pET-24a-PKG50-P4VP4

Experimental Approach

We isolated pET-24a vectors from bacterial solutions primarily by centrifugation. The vectors were then obtained from the remains in the absorption column. Subsequently, we linearized the vectors using restriction enzymes and conducted electrophoresis to analyze the products. The electrophoresis result displayed consistency toward the expected outcome (PKG50-P4VP4 is 2000 bp); we selected colonies and sent them directly for sequencing. Figure 2 shows the success of pET24a-PKG50-P4VP4 construction.

Figure 2: The results of pET24a-PKG50-P4VP4
Fig. 2. The results of pET24a-PKG50-P4VP4

Characterization/Measurement

Later, the plasmid pET-24a-PKG50-P4VP4 was transferred to E. coli DH5α to replicate. The extracted plasmid was transferred into E. coli BL21, which can help express His-PKG50-P4VP4. After the colony PCR of E. coli BL21 was finished and verified, the bacteria were cultured and treated with 0.2 mM IPTG, which can promote protein expression. After promoting the protein expression overnight, the protein was purified via His-tag Purification Resin and went through SDS-PAGE electrophoresis. The target protein PKG50-P4VP4 has a size of 68.1 kDa.

Figure 3: The expression of PKG50-P4VP4 using E. coli BL21.
Fig. 3. The expression of PKG50-P4VP4 using E. coli BL21.

Characterization of Collagen Oligomers

Collagen of the C-D-E-VP4 complex (in a 1:1:1 ratio) was diluted to a concentration of 0.5 mg/mL and incubated at 37°C for 1 hour before undergoing native-PAGE and SEC analysis. As illustrated in Figure 4, the samples were divided into two distinct clusters: high-molecular-weight and low-molecular-weight states. Each cluster contained multiple bands, indicative of varying degrees of proline hydroxylation. Based on the construct design, we hypothesized that the high-molecular-weight clusters represented the trimer assemblies, while the low-molecular-weight clusters corresponded to the monomers. This hypothesis was confirmed by the SEC analysis, as depicted in Figure 4. The peaks for the C-D-E-VP4 complex also ranged from 0.5 to 0.8 CV, with the prominent peaks at 0.57 CV, 0.68 CV, 0.72 CV, and 0.77 CV, indicating a trimer at 0.57 CV and the other peaks corresponding to the monomers of C, D, and E.

Figure 4: Native-PAGE analysis of oligomeric states of collagen C-D-E complex.
Fig. 4. Native-PAGE analysis of oligomeric states of collagen C-D-E complex (left); Size exclusion chromatographic (SEC) analysis of oligomeric states of collagen C-D-E complex (right).

References

[1] Gauba V, Hartgerink JD. Self-assembled heterotrimeric collagen triple helices directed through electrostatic interactions. J Am Chem Soc. 2007 Mar 7;129(9):2683-90.
[2] Liu Zezhong; Zhou Jie; Zhu Yun; Lu Lu; Jiang Shibo; School of Basic Medical Sciences, Fudan University; Department of Pharmacology, School of Pharmacy, Fudan University; Institute of Biophysics, Chinese Academy of Sciences.

[edit]
Categories
Parameters
None